Thank you to @AHAScience and @ACCinTouch for including the patient voice in the new 2024 #HCM Guidelines! It was an honor and a pleasure to serve on the Writing Committee.
https://t.co/hwFSwnnfq3
2024 Updated Guidelines for Management and Treatment of HCM https://t.co/hwFSwnnfq3 The new guidelines are out! Check out what is new. Thanks to @SteveOmmen@CarolynHoMD for inviting me to serve on the writing committee. It was a privilege.
Hypertrophic Cardiomyopathy (HCM) remains a common genetic heart disease in populations throughout the world.
The 2024 Guideline for the Management of Hypertrophic Cardiomyopathy was published today in @CircAHA.
✍🏼 @SteveOmmen
📷 Recommended Evaluation & Testing for HCM
Is pregnancy safe in patients with hypertrophic cardiomyopathy (HCM) and what should be monitored?
Register for free and access the on-demand webinar anytime from the comfort of your home or office and gain CE credit(s). ⬇️
#pregnancy#MedEd https://t.co/RRGnm6hNVK
Check out the HCMS 2023 Sessions Abstract Publication in @JCardFail that includes:
🫀Efficacy and safety of mavacamten treatment
🫀 AAV9-Mediated Gene Therapy
🫀 Characteristics of Patients in SEQUOIA-HCM
🫀 & much more!
https://t.co/XIfqnwHb0q
#HCM#Cardiology#CardioTwitter
Do you or a relative have experience of #cardiomyopathy + aged 16 or above? CureHeart: Patient Perspectives study (questionnaire) now open. We will invite some people for optional research interviews. Info: https://t.co/RV4zhVvhvW #CureHeart#HeartHealth#CardioTwitter *Please RT
HCM patients who have cancer should not be under-treated because of their heart condition. In general, they tolerate treatments well!
Kudos to Mattia Zampieri and the Italian-Dutch team 🙏🙏🙏